Big pharma goes shopping as “patent cliff” puts more than $225 billion in revenues at risk.
You are here: Home / Top Stories / : Drugmakers’ deal making will plow ahead despite antitrust scrutiny, analysts say
Market News and Views
Big pharma goes shopping as “patent cliff” puts more than $225 billion in revenues at risk.